English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

In December 2005, a Working Party for the Joint British Societies (JBS-2) published guidelines on the prevention of cardiovascular disease in clinical practice ‘ to promote a consistent multi-disciplinary approach to the management of people with established atherosclerotic cardiovascular disease and those at high risk of developing symptomatic atherosclerotic disease ’.1 The Working Party has produced a comprehensive document that addresses most aspects of cardiovascular risk prevention. However important issues arise from the JBS-2 guidance in relation to: (i) screening for new diabetes and (ii) the investigation of impaired glucose tolerance.In the section on risk factor assessment, JBS-2 recommends: ‘ if non-fasting glucose is ⩾6.1 mmol/l then measure fasting glucose for evidence of impaired glucose regulation or new diabetes. If this fasting glucose measurement is normal (⩽6.0 mmol/l) there is no need to repeat it ’. JBS-2 is proposing that a single normal fasting glucose measurement is an adequate screening test for new diabetes. There is however a large body of evidence to refute the wisdom of this pragmatic approach, particularly in the ‘at risk’ population in question.2–8### Fasting glucose is a poor indicator of impaired glucose regulationThe DECODE study group (Diabetes Epidemiology: Collaborative analysis of Diagnostic criteria in Europe) reported a normal fasting blood glucose (FBG) in 31% of subjects confirmed as diabetic on oral glucose tolerance testing (OGTT).2 Evidence from the Euro Heart Survey emphasizes that without the use of OGTT, almost two-thirds of patients with impaired glucose regulation (new detected diabetes or impaired glucose tolerance, IGT) would remain undiagnosed.3 This holds true for both acute and …

The JBS-2 guidelines on prevention of cardiovascular disease in clinical practice: an opportunity missed